Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

We shall overcome (drug resistance) some day.

Sharma GG, Mologni L.

Oncotarget. 2019 Jan 4;10(2):84-85. doi: 10.18632/oncotarget.26550. eCollection 2019 Jan 4. No abstract available.

2.

Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling.

Ceccon M, Mauri M, Massimino L, Giudici G, Piazza R, Gambacorti-Passerini C, Mologni L.

Cancers (Basel). 2018 Dec 12;10(12). pii: E509. doi: 10.3390/cancers10120509.

3.

Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma.

Menotti M, Ambrogio C, Cheong TC, Pighi C, Mota I, Cassel SH, Compagno M, Wang Q, Dall'Olio R, Minero VG, Poggio T, Sharma GG, Patrucco E, Mastini C, Choudhari R, Pich A, Zamo A, Piva R, Giliani S, Mologni L, Collings CK, Kadoch C, Gambacorti-Passerini C, Notarangelo LD, Anton IM, Voena C, Chiarle R.

Nat Med. 2019 Jan;25(1):130-140. doi: 10.1038/s41591-018-0262-9. Epub 2018 Dec 3.

4.

Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer.

Redaelli S, Ceccon M, Zappa M, Sharma GG, Mastini C, Mauri M, Nigoghossian M, Massimino L, Cordani N, Farina F, Piazza R, Gambacorti-Passerini C, Mologni L.

Cancer Res. 2018 Dec 15;78(24):6866-6880. doi: 10.1158/0008-5472.CAN-18-1867. Epub 2018 Oct 15.

PMID:
30322862
5.

Synergistic activity of dasatinib in combination with β-catenin blockade in colorectal cancer cells.

Mologni L.

Eur J Cancer. 2018 Nov;104:231-232. doi: 10.1016/j.ejca.2018.08.025. Epub 2018 Oct 12. No abstract available.

PMID:
30322680
6.

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells.

Mologni L, Costanza M, Sharma GG, Viltadi M, Massimino L, Citterio S, Purgante S, Raman H, Pirola A, Zucchetti M, Piazza R, Gambacorti-Passerini C.

Neoplasia. 2018 May;20(5):467-477. doi: 10.1016/j.neo.2018.02.009. Epub 2018 Mar 30.

7.

β-catenin knockdown promotes NHERF1-mediated survival of colorectal cancer cells: implications for a double-targeted therapy.

Saponaro C, Sergio S, Coluccia A, De Luca M, La Regina G, Mologni L, Famiglini V, Naccarato V, Bonetti D, Gautier C, Gianni S, Vergara D, Salzet M, Fournier I, Bucci C, Silvestri R, Passerini CG, Maffia M, Coluccia AML.

Oncogene. 2018 Jun;37(24):3301-3316. doi: 10.1038/s41388-018-0170-y. Epub 2018 Mar 19.

8.

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

Sharma GG, Mota I, Mologni L, Patrucco E, Gambacorti-Passerini C, Chiarle R.

Cancers (Basel). 2018 Feb 28;10(3). pii: E62. doi: 10.3390/cancers10030062. Review.

9.

Novel targeted therapeutics for MEN2.

Redaelli S, Plaza-Menacho I, Mologni L.

Endocr Relat Cancer. 2018 Feb;25(2):T53-T68. doi: 10.1530/ERC-17-0297. Review.

PMID:
29348306
10.

Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer.

Awad MM, Mastini C, Blasco RB, Mologni L, Voena C, Mussolin L, Mach SL, Adeni AE, Lydon CA, Sholl LM, Jänne PA, Chiarle R.

Oncotarget. 2017 Sep 23;8(54):92265-92274. doi: 10.18632/oncotarget.21182. eCollection 2017 Nov 3.

11.

Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients.

Mologni L, Piazza R, Khandelwal P, Pirola A, Gambacorti-Passerini C.

Am J Hematol. 2017 Oct;92(10):E623-E625. doi: 10.1002/ajh.24865. Epub 2017 Aug 17. No abstract available.

12.

Discovery of wt RET and V804M RET Inhibitors: From Hit to Lead.

Mologni L, Dalla Via M, Chilin A, Palumbo M, Marzaro G.

ChemMedChem. 2017 Aug 22;12(16):1390-1398. doi: 10.1002/cmdc.201700243. Epub 2017 Jul 25.

PMID:
28639308
13.

The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhibition.

Mologni L, Magistroni V, Casuscelli F, Montemartini M, Gambacorti-Passerini C.

J Cancer. 2017 Jan 1;8(1):140-145. doi: 10.7150/jca.15838. eCollection 2017.

14.

Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma.

Redaelli S, Ceccon M, Antolini L, Rigolio R, Pirola A, Peronaci M, Gambacorti-Passerini C, Mologni L.

Oncotarget. 2016 Nov 8;7(45):72886-72897. doi: 10.18632/oncotarget.12128.

15.

RET kinase inhibitors: a review of recent patents (2012-2015).

Mologni L, Gambacorti-Passerini C, Goekjian P, Scapozza L.

Expert Opin Ther Pat. 2017 Jan;27(1):91-99. Epub 2016 Sep 26. Review.

PMID:
27646564
16.

Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.

Ardini E, Menichincheri M, Banfi P, Bosotti R, De Ponti C, Pulci R, Ballinari D, Ciomei M, Texido G, Degrassi A, Avanzi N, Amboldi N, Saccardo MB, Casero D, Orsini P, Bandiera T, Mologni L, Anderson D, Wei G, Harris J, Vernier JM, Li G, Felder E, Donati D, Isacchi A, Pesenti E, Magnaghi P, Galvani A.

Mol Cancer Ther. 2016 Apr;15(4):628-39. doi: 10.1158/1535-7163.MCT-15-0758. Epub 2016 Mar 3.

17.

Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency.

Ceccon M, Merlo MEB, Mologni L, Poggio T, Varesio LM, Menotti M, Bombelli S, Rigolio R, Manazza AD, Di Giacomo F, Ambrogio C, Giudici G, Casati C, Mastini C, Compagno M, Turner SD, Gambacorti-Passerini C, Chiarle R, Voena C.

Oncogene. 2016 Jul 21;35(29):3854-3865. doi: 10.1038/onc.2015.456. Epub 2015 Dec 14.

18.

Current and future treatment of anaplastic lymphoma kinase-rearranged cancer.

Mologni L.

World J Clin Oncol. 2015 Oct 10;6(5):104-8. doi: 10.5306/wjco.v6.i5.104.

19.

Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors.

Voena C, Menotti M, Mastini C, Di Giacomo F, Longo DL, Castella B, Merlo MEB, Ambrogio C, Wang Q, Minero VG, Poggio T, Martinengo C, D'Amico L, Panizza E, Mologni L, Cavallo F, Altruda F, Butaney M, Capelletti M, Inghirami G, Jänne PA, Chiarle R.

Cancer Immunol Res. 2015 Dec;3(12):1333-1343. doi: 10.1158/2326-6066.CIR-15-0089. Epub 2015 Sep 29.

20.

Expanding the portfolio of anti-ALK weapons.

Mologni L.

Transl Lung Cancer Res. 2015 Feb;4(1):5-7. doi: 10.3978/j.issn.2218-6751.2014.07.02.

21.

NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.

Mologni L, Ceccon M, Pirola A, Chiriano G, Piazza R, Scapozza L, Gambacorti-Passerini C.

Oncotarget. 2015 Mar 20;6(8):5720-34.

22.

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.

Fontana D, Ceccon M, Gambacorti-Passerini C, Mologni L.

Cancer Med. 2015 Jul;4(7):953-65. doi: 10.1002/cam4.413. Epub 2015 Feb 26.

23.

Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.

Ceccon M, Mologni L, Giudici G, Piazza R, Pirola A, Fontana D, Gambacorti-Passerini C.

Mol Cancer Res. 2015 Apr;13(4):775-83. doi: 10.1158/1541-7786.MCR-14-0157. Epub 2014 Nov 24. Erratum in: Mol Cancer Res. 2015 Oct;13(10):1441.

24.

Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.

Plaza-Menacho I, Mologni L, McDonald NQ.

Cell Signal. 2014 Aug;26(8):1743-52. doi: 10.1016/j.cellsig.2014.03.032. Epub 2014 Apr 3. Review.

PMID:
24705026
25.

Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients.

Gambacorti Passerini C, Farina F, Stasia A, Redaelli S, Ceccon M, Mologni L, Messa C, Guerra L, Giudici G, Sala E, Mussolin L, Deeren D, King MH, Steurer M, Ordemann R, Cohen AM, Grube M, Bernard L, Chiriano G, Antolini L, Piazza R.

J Natl Cancer Inst. 2014 Feb;106(2):djt378. doi: 10.1093/jnci/djt378.

PMID:
24491302
26.

Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors.

Tardy S, Orsato A, Mologni L, Bisson WH, Donadoni C, Gambacorti-Passerini C, Scapozza L, Gueyrard D, Goekjian PG.

Bioorg Med Chem. 2014 Feb 15;22(4):1303-12. doi: 10.1016/j.bmc.2014.01.007. Epub 2014 Jan 10.

PMID:
24468632
27.

Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.

Mologni L, Redaelli S, Morandi A, Plaza-Menacho I, Gambacorti-Passerini C.

Mol Cell Endocrinol. 2013 Sep 5;377(1-2):1-6. doi: 10.1016/j.mce.2013.06.025. Epub 2013 Jun 27.

PMID:
23811235
28.

Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex.

Piazza R, Magistroni V, Mogavero A, Andreoni F, Ambrogio C, Chiarle R, Mologni L, Bachmann PS, Lock RB, Collini P, Pelosi G, Gambacorti-Passerini C.

Neoplasia. 2013 May;15(5):511-22.

29.

Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.

Ceccon M, Mologni L, Bisson W, Scapozza L, Gambacorti-Passerini C.

Mol Cancer Res. 2013 Feb;11(2):122-32. doi: 10.1158/1541-7786.MCR-12-0569. Epub 2012 Dec 13.

30.

Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells.

Mologni L, Brussolo S, Ceccon M, Gambacorti-Passerini C.

PLoS One. 2012;7(12):e51449. doi: 10.1371/journal.pone.0051449. Epub 2012 Dec 5.

31.

Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.

Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A, Antolini L, Mologni L, Donadoni C, Papaemmanuil E, Schnittger S, Kim DW, Boultwood J, Rossi F, Gaipa G, De Martini GP, di Celle PF, Jang HG, Fantin V, Bignell GR, Magistroni V, Haferlach T, Pogliani EM, Campbell PJ, Chase AJ, Tapper WJ, Cross NC, Gambacorti-Passerini C.

Nat Genet. 2013 Jan;45(1):18-24. doi: 10.1038/ng.2495. Epub 2012 Dec 9.

32.

Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.

Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M, Viltadi M, Flynn D, Gambacorti-Passerini C.

Am J Hematol. 2012 Nov;87(11):E125-8. doi: 10.1002/ajh.23338. Epub 2012 Oct 9.

33.

Inhibitors of the anaplastic lymphoma kinase.

Mologni L.

Expert Opin Investig Drugs. 2012 Jul;21(7):985-94. doi: 10.1517/13543784.2012.690031. Epub 2012 May 22. Review.

PMID:
22612599
34.

ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells.

Magistroni V, Mologni L, Sanselicio S, Reid JF, Redaelli S, Piazza R, Viltadi M, Bovo G, Strada G, Grasso M, Gariboldi M, Gambacorti-Passerini C.

PLoS One. 2011;6(11):e28162. doi: 10.1371/journal.pone.0028162. Epub 2011 Nov 30.

35.

Dissection of the RET/β-catenin interaction in the TPC1 thyroid cancer cell line.

Tartari CJ, Donadoni C, Manieri E, Mologni L, Mina PD, Villa A, Gambacorti-Passerini C.

Am J Cancer Res. 2011;1(6):716-25. Epub 2011 Jun 1.

36.

Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors.

af Gennäs GB, Mologni L, Ahmed S, Rajaratnam M, Marin O, Lindholm N, Viltadi M, Gambacorti-Passerini C, Scapozza L, Yli-Kauhaluoma J.

ChemMedChem. 2011 Sep 5;6(9):1680-92. doi: 10.1002/cmdc.201100168. Epub 2011 Jun 30.

PMID:
21721129
37.

Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism.

Plaza-Menacho I, Morandi A, Mologni L, Boender P, Gambacorti-Passerini C, Magee AI, Hofstra RM, Knowles P, McDonald NQ, Isacke CM.

J Biol Chem. 2011 May 13;286(19):17292-302. doi: 10.1074/jbc.M110.168500. Epub 2011 Mar 22.

38.

Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells.

Marfe G, Di Stefano C, Gambacurta A, Ottone T, Martini V, Abruzzese E, Mologni L, Sinibaldi-Salimei P, de Fabritis P, Gambacorti-Passerini C, Amadori S, Birge RB.

Exp Hematol. 2011 Jun;39(6):653-665.e6. doi: 10.1016/j.exphem.2011.02.013. Epub 2011 Mar 8.

PMID:
21392556
39.

Development of RET kinase inhibitors for targeted cancer therapy.

Mologni L.

Curr Med Chem. 2011;18(2):162-75. Review.

PMID:
21110809
40.

Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2.

Mologni L, Dekhil H, Ceccon M, Purgante S, Lan C, Cleris L, Magistroni V, Formelli F, Gambacorti-Passerini CB.

Cancer Res. 2010 Sep 15;70(18):7253-63. doi: 10.1158/0008-5472.CAN-10-1108. Epub 2010 Sep 7.

41.

Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold.

Brandt W, Mologni L, Preu L, Lemcke T, Gambacorti-Passerini C, Kunick C.

Eur J Med Chem. 2010 Jul;45(7):2919-27. doi: 10.1016/j.ejmech.2010.03.017. Epub 2010 Mar 19.

PMID:
20409618
42.

Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors.

Mologni L, Rostagno R, Brussolo S, Knowles PP, Kjaer S, Murray-Rust J, Rosso E, Zambon A, Scapozza L, McDonald NQ, Lucchini V, Gambacorti-Passerini C.

Bioorg Med Chem. 2010 Feb 15;18(4):1482-96. doi: 10.1016/j.bmc.2010.01.011. Epub 2010 Jan 11.

PMID:
20117004
43.

Valproic acid enhances bosutinib cytotoxicity in colon cancer cells.

Mologni L, Cleris L, Magistroni V, Piazza R, Boschelli F, Formelli F, Gambacorti-Passerini C.

Int J Cancer. 2009 Apr 15;124(8):1990-6. doi: 10.1002/ijc.24158.

44.

BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells.

Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, Gambacorti-Passerini C.

Mol Cancer Res. 2008 May;6(5):751-9. doi: 10.1158/1541-7786.MCR-07-2001. Epub 2008 May 5.

45.

Characterization of compound 584, an Abl kinase inhibitor with lasting effects.

Puttini M, Redaelli S, Moretti L, Brussolo S, Gunby RH, Mologni L, Marchesi E, Cleris L, Donella-Deana A, Drueckes P, Sala E, Lucchini V, Kubbutat M, Formelli F, Zambon A, Scapozza L, Gambacorti-Passerini C.

Haematologica. 2008 May;93(5):653-61. doi: 10.3324/haematol.12212. Epub 2008 Mar 26.

46.

Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy.

Gunby RH, Sala E, Tartari CJ, Puttini M, Gambacorti-Passerini C, Mologni L.

Anticancer Agents Med Chem. 2007 Nov;7(6):594-611. Review.

PMID:
18045055
47.

Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.

Plaza-Menacho I, Mologni L, Sala E, Gambacorti-Passerini C, Magee AI, Links TP, Hofstra RM, Barford D, Isacke CM.

J Biol Chem. 2007 Oct 5;282(40):29230-40. Epub 2007 Jul 30.

48.

Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation.

Coluccia AM, Vacca A, Duñach M, Mologni L, Redaelli S, Bustos VH, Benati D, Pinna LA, Gambacorti-Passerini C.

EMBO J. 2007 Mar 7;26(5):1456-66. Epub 2007 Feb 22.

49.

Targeted deletion of the muscular dystrophy gene myotilin does not perturb muscle structure or function in mice.

Moza M, Mologni L, Trokovic R, Faulkner G, Partanen J, Carpén O.

Mol Cell Biol. 2007 Jan;27(1):244-52. Epub 2006 Oct 30.

50.

Inhibition of RET tyrosine kinase by SU5416.

Mologni L, Sala E, Cazzaniga S, Rostagno R, Kuoni T, Puttini M, Bain J, Cleris L, Redaelli S, Riva B, Formelli F, Scapozza L, Gambacorti-Passerini C.

J Mol Endocrinol. 2006 Oct;37(2):199-212.

PMID:
17032739

Supplemental Content

Loading ...
Support Center